Novavax Inc (NVAX)
Novavax develops vaccines and licenses its Matrix-M adjuvant to drug makers and governments worldwide. It last closed at $7.96 on Nov 17, down 1.24% on the day. The average 12-month price target from 2 analysts is $12.00 (+50.8% from the last close), with a high of $16.00 and a low of $8.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in NVAX, 0% of them bullish and 100% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From NVAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on NVAX in the past 90 days. The average target is $12.00, with a high of $16.00 and a low of $8.00, compared with the last close of $7.96.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | B. Riley Securities | Reiterated | Buy | $16 |
| Oct 15 | Citigroup | Maintained | Sell | $8 |
Technical Analysis
The stock is 23% below its 20 day and 31% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.85, and the nearest resistance the Pivot at $7.99.
| RSI (14) | 34.74 | Weak, oversold below 30 | Neutral |
| MACD | -0.58 | Below its signal line | Bearish |
| Stochastic | 3.7 | Near the bottom of its range | Oversold |
| ADX (14) | 26.1 | Trending down | |
| Williams %R | -97.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -197.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.79 | Typical daily range, 9.9% of price |
| RSI (14) | 43.46 | Middle of its range | Neutral |
| MACD | 0.18 | Below its signal line | Bearish |
| Stochastic | 24.7 | Middle of its range | Neutral |
| ADX (14) | 28.7 | Trending up | |
| Williams %R | -97.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -85.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −15.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.51 | Typical daily range, 18.9% of price |
What happened before
See how NVAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NVAX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in NVAX in the last 90 days.
NVAX Institutional Ownership
Full report →- ▼104 buying vs 125 selling
- ▲Held by funds +1.6 pts
- ▼Funds holding -10
- ▼Superinvestors: 1 added, 3 cut
- ▼Put/call 2.92 to 4.34
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 261 | 271 | −3.7% |
| In funds' top 10 | 3 | 2 | +50.0% |
| Held by funds | 72.8% | 71.2% | +1.6 pts |
| New / increased | 30 / 74 | 40 / 76 | −10.3% |
| Reduced / sold out | 85 / 40 | 88 / 32 | +4.2% |
| Put/call ratio | 4.34 | 2.92 | +48.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NVAX is in one of them and how their past NVAX trades turned out.
NVAX News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NVAX in an article yet. Here's the latest on the wider market.
NVAX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Novavax
Novavax is a vaccine company based in Gaithersburg, Maryland. It develops vaccines using a platform built on protein nanoparticles, and its COVID-19 vaccine, Nuvaxovid, is sold with Sanofi leading commercialization. The company also licenses its Matrix-M adjuvant, which helps vaccines produce a stronger immune response, to partners such as the Serum Institute of India and other drug makers. Its customers include national governments and global pharmaceutical companies.
- Headquarters
- Gaithersburg, MD
- Founded
- 1987
- Website
- es.novavax.com ↗



